Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD.
Heerspink HJL, Inker LA, Tighiouart H, Collier WH, Haaland B, Luo J, Appel GB, Chan TM, Estacio RO, Fervenza F, Floege J, Imai E, Jafar TH, Lewis JB, Kam-Tao Li P, Locatelli F, Maes BD, Perna A, Perrone RD, Praga M, Schena FP, Wanner C, Xie D, Greene T; on behalf of CKD-EPI CT. Heerspink HJL, et al. Among authors: maes bd. J Am Soc Nephrol. 2023 Jun 1;34(6):955-968. doi: 10.1681/ASN.0000000000000117. Epub 2023 Mar 15. J Am Soc Nephrol. 2023. PMID: 36918388 Clinical Trial.
Evaluation of Variation in the Performance of GFR Slope as a Surrogate End Point for Kidney Failure in Clinical Trials that Differ by Severity of CKD.
Collier W, Inker LA, Haaland B, Appel GB, Badve SV, Caravaca-Fontán F, Chalmers J, Floege J, Goicoechea M, Imai E, Jafar TH, Lewis JB, Li PKT, Locatelli F, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Heerspink HJL, Greene T; Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)*. Collier W, et al. Among authors: maes bd. Clin J Am Soc Nephrol. 2023 Feb 1;18(2):183-192. doi: 10.2215/CJN.0000000000000050. Epub 2023 Jan 19. Clin J Am Soc Nephrol. 2023. PMID: 36754007 Free PMC article.
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial.
Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, Diva UA, Floege J, Gesualdo L, Inrig JK, Kohan DE, Komers R, Kooienga LA, Lafayette R, Maes B, Małecki R, Mercer A, Noronha IL, Oh SW, Peh CA, Praga M, Preciado P, Radhakrishnan J, Rheault MN, Rote WE, Tang SCW, Tesar V, Trachtman H, Trimarchi H, Tumlin JA, Wong MG, Perkovic V; DUPRO steering committee and PROTECT Investigators. Rovin BH, et al. Lancet. 2023 Dec 2;402(10417):2077-2090. doi: 10.1016/S0140-6736(23)02302-4. Epub 2023 Nov 3. Lancet. 2023. PMID: 37931634 Clinical Trial.
Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Rossing P, Anker SD, Filippatos G, Pitt B, Ruilope LM, Birkenfeld AL, McGill JB, Rosas SE, Joseph A, Gebel M, Roberts L, Scheerer MF, Bakris GL, Agarwal R; FIDELIO-DKD and FIGARO-DKD Investigators. Rossing P, et al. Diabetes Care. 2022 Dec 1;45(12):2991-2998. doi: 10.2337/dc22-0294. Diabetes Care. 2022. PMID: 35972218 Free PMC article. Clinical Trial.
Clinicopathological characteristics and disease chronicity in native kidney biopsies in Flanders.
Deleersnijder D, Laurens W, De Meester J, Cleenders E, Dendooven A, Lerut E, De Vriese AS, Dejagere T, Helbert M, Hellemans R, Koshy P, Maes B, Pipeleers L, Van Craenenbroeck AH, Van Laecke S, Vande Walle J, Couttenye MM, Meeus G, Sprangers B; FCGG collaborative group. Deleersnijder D, et al. Clin Kidney J. 2022 Sep 14;16(1):125-137. doi: 10.1093/ckj/sfac208. eCollection 2023 Jan. Clin Kidney J. 2022. PMID: 36726429 Free PMC article.
A meta-analysis of GFR slope as a surrogate endpoint for kidney failure.
Inker LA, Collier W, Greene T, Miao S, Chaudhari J, Appel GB, Badve SV, Caravaca-Fontán F, Del Vecchio L, Floege J, Goicoechea M, Haaland B, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PKT, Maes BD, Neuen BL, Perrone RD, Remuzzi G, Schena FP, Wanner C, Wetzels JFM, Woodward M, Heerspink HJL; CKD-EPI Clinical Trials Consortium. Inker LA, et al. Among authors: maes bd. Nat Med. 2023 Jul;29(7):1867-1876. doi: 10.1038/s41591-023-02418-0. Epub 2023 Jun 17. Nat Med. 2023. PMID: 37330614
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression.
Neuen BL, Tighiouart H, Heerspink HJL, Vonesh EF, Chaudhari J, Miao S, Chan TM, Fervenza FC, Floege J, Goicoechea M, Herrington WG, Imai E, Jafar TH, Lewis JB, Li PK, Locatelli F, Maes BD, Perrone RD, Praga M, Perna A, Schena FP, Wanner C, Wetzels JFM, Woodward M, Xie D, Greene T, Inker LA; CKD-EPI Clinical Trials. Neuen BL, et al. Among authors: maes bd. J Am Soc Nephrol. 2022 Feb;33(2):291-303. doi: 10.1681/ASN.2021070948. Epub 2021 Dec 3. J Am Soc Nephrol. 2022. PMID: 34862238 Free PMC article.
Association of Treatment Effects on Early Change in Urine Protein and Treatment Effects on GFR Slope in IgA Nephropathy: An Individual Participant Meta-analysis.
Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, Mercer A, Appel GB, Donadio JV, Floege J, Li PKT, Maes BD, Locatelli F, Praga M, Schena FP, Levey AS, Greene T. Inker LA, et al. Among authors: maes bd. Am J Kidney Dis. 2021 Sep;78(3):340-349.e1. doi: 10.1053/j.ajkd.2021.03.007. Epub 2021 Mar 26. Am J Kidney Dis. 2021. PMID: 33775708 Free PMC article. Review.
Performance of GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Statistical Simulation.
Greene T, Ying J, Vonesh EF, Tighiouart H, Levey AS, Coresh J, Herrick JS, Imai E, Jafar TH, Maes BD, Perrone RD, Del Vecchio L, Wetzels JFM, Heerspink HJL, Inker LA. Greene T, et al. Among authors: maes bd. J Am Soc Nephrol. 2019 Sep;30(9):1756-1769. doi: 10.1681/ASN.2019010009. Epub 2019 Jul 10. J Am Soc Nephrol. 2019. PMID: 31292198 Free PMC article.
50 results